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Abstract
 
Most of the patients with congenital heart diseases express
the atrial myosin light chain 1 (ALC-1) in the right ventri-
cle. We investigated the functional consequences of ALC-1
expression on the myosin cycling kinetics in the intact sar-
comeric structure using multicellular demembranated fibers
(“skinned fibers”) from the right ventricular infundibulum
of patients with Tetralogy of Fallot (TOF), double outlet
right ventricle (DORV), and infundibular pulmonary steno-
sis (IPS). Force-velocity relation was analyzed by the con-
stant-load technique at maximal Ca
 
2
 
1
 
 activation (pCa 4.5).
Half-time of tension develoment (
 
t
 
1/2
 
) was investigated by
monitoring contraction initiation upon photolytic release of
ATP from caged-ATP in rigor. The patients investigated
here expressed between 0 and 27% ALC-1. There was a sta-
tistically significant correlation between ALC-1 and maxi-
mal shortening velocity (
 
V
 
max
 
) which rose 1.87-fold from 1.2
muscle length per second (ML/s) to 2.25 ML/s in a normal
(0% ALC-1) and diseased (19.9% ALC-1) ventricle. Half-
time of tension development decreased 1.85-fold with in-
creasing ALC-1 expression (
 
t
 
1
 
/2
 
 was 0.252 s and 0.136 s at 2
and 18.4% ALC-1, respectively). We conclude that the ex-
pression of ALC-1 in the human heart modulates cross-
bridge cycling kinetics accelerating shortening velocity and
isometric tension production. (
 
J. Clin. Invest.
 
 1996. 98:467–
473.) Key words: myosin light chains 
 
• 
 
human heart 
 
• 
 
car-
diac contractility 
 
• 
 
congenital heart disease 
 
• 
 
Tetralogy of
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Introduction
 
The type II myosin molecule of the heart is a hexamer consist-
ing of two heavy chains (MHC;
 
1
 
 200 kD) each associated with
light chains (MLC; 18–28 kD). Two cardiac-specific genes cod-
ing for MHC are expressed, namely the 
 
a
 
-MHC and the
 
b
 
-MHC located in tandem on chromosome 14 (2–4). The
MLC types are classified into essential MLC (or MLC-1) and
regulatory (phosphorylatable) MLC (or MLC-2) (5, 6). Recent
X-ray crystallographic analysis demonstrated that both essen-
tial and regulatory MLC are associated with the neck region of
the myosin-S1 fragment (7). In the human heart, five different
MLC isoforms exist which are expressed in a tissue-specific
manner: there are three regulatory (phosphorylatable) myosin
light chains, namely two ventricular-specific (VLC-2 and VLC-
2*) and an atrial-specific (ALC-2) (8, 9). The ventricular regu-
latory light chains are monophosphorlyated each, while the
ALC-2 may be mono- and diphosphorylated (9). Two essential
myosin light chain isoforms are produced by two different
genes, namely a VLC-1 which is the same isoform as the MLC-1s
present in adult slow skeletal muscle, and an atrial-specific
(ALC-1) isoform (10). Two different ALC-1 transcripts have
been described on the mRNA level which differed in their 5
 
9
 
-
and 3
 
9
 
- untranslated regions having identical protein coding se-
quences (11). In the murine, two E boxes (which interact with
muscle-specific regulatory proteins of the MyoD family) and a
diverged CArG box (which binds the serum response factor)
exist within the first 630 bp of the ALC-1 promoter region
(12). E boxes have been shown to be sufficient for ALC-1 tran-
scription regulation during skeletal muscle differentiation (12).
Human embryos express large amounts of ALC-1 in the whole
heart and in skeletal muscle (8). Therefore, the ALC-1 was
designated as the embryonic MLC (MLC-1emb) (for review
see 13). ALC-1 expression in the ventricle decreases to unde-
tectable levels during early postnatal development but persists
in the atrium for the whole life (8, 14, 15). The situation is dif-
ferent in patients with congenital heart disease, e.g., with Te-
tralogy of Fallot (TOF), double-outlet right ventricle (DORV),
and infundibular pulmonary stenosis (IPS). TOF is a complex
congenital heart disease characterized by four components: a
right ventricular infundibular stenosis, a ventricular septal de-
fect, a dextroposed aorta overriding the interventricular septal
defect, and right ventricular hypertrophy (16). DORV is con-
sidered as a partial transposition complex in which both great
arteries arise from the right ventricle. Our patients were from
the “Fallot-type” (infundibular stenosis, ventricular septal de-
fect, right ventricular hypertrophy). IPS is a pulmonary in-
fundibular stenosis narrowing the right ventricular outflow
tract associated with hypertrophy of the right ventricle. The
hypertrophied right ventricle of children with TOF expresses
large amounts of ALC-1 in the ventricle up to adulthood (14).
Similarly, the hypertrophied left ventricle of patients with is-
chaemic or dilative cardiomyopathy reexpresses ALC-1 (17).
Surgical intervention with subsequent normalization of the he-
modynamic state decreases ALC-1 expression in these pa-
tients (18).
However, the physiological role of the essential light chains
is still not well characterized. To selectively analyze the physi-
ological function of essential MLC in the human heart, we
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2D, two-dimensional; VLC, ventricular light chain.
 
 468
 
Morano et al.
 
studied cross-bridge reaction in demembranated multicellular
heart preparations (“skinned fibers”) from right ventricular
heart tissue of patients with different congenital heart diseases
(TOF, DORV, IPS). These tissue specimens are of special in-
terest since they contain myosin cross-bridges which differ
only by their essential MLC isoforms having the subunit com-
positions: 
 
b
 
-MHC, ALC-1, VLC-1, VLC-2, and VLC-2*. Nor-
mal ventricular myosin consists of 
 
b
 
-MHC, VLC-1, VLC-2,
and VLC-2*. Therefore, we obtained the opportunity to selec-
tively analyze the role of essential MLC on myosin cross-
bridge cycling and cardiac contractility. The rationale to use
demembranated fibers for analysis of cross-bridge cycling ki-
netics is supported by a recent report which demonstrated that
cross-bridge cycling in skinned and intact cardiac tissue is the
same (29). To define cross-bridge cycling kinetics, we deter-
mined the maximal shortening velocity (
 
V
 
max
 
) as well as half-
time of tension development (
 
t
 
1/2
 
) of skinned fibers. The same
preparations were used to analyze ALC-1 expression on the
protein level.
In the intact contractile structure, the myosin cross-bridge
(M) reaction is assumed to comprise complex interactions with
actin (A) coupled with the hydrolysis of ATP to ADP and Pi.
Myosin undergoes changes of its affinity during the cycle being
strongly attached to actin (having high actin affinity) or weakly
attached (having low actin affinity) (30, 31). Force production
is considered to be associated with the Pi release step and the
transition from weakly (nonforce generating) to strongly at-
tached (force generating) states (cf. 32). Isotonic shortening,
however is suggested to be rate limited by cross-bridge detach-
ment and the ADP release (33).
Velocity of muscle shortening was analyzed by applying
quick releases during isometric steady state tension under con-
stant load conditions. To exclude the influence of changes in
the expression of regulatory proteins on cross-bridge cycling,
we activated the fibers with maximal free Ca
 
2
 
1
 
 concentration
(pCa 4.5). We determined the half-time of the transition from
nonforce into force generating states by monitoring the force
production upon photolytical release of ATP from caged-ATP
in a low-tension rigor state in the presence of maximally acti-
vating Ca
 
2
 
1
 
 concentration (cf. 21). Low-tension rigor is ob-
tained by the presence of 2,3-butanedione monoxime (BDM)
in the rigor solution. BDM binds to the myosin cross-bridges
and inhibits the transition into force-generating states. Follow-
ing the light flash, ATP is released and binds to myosin which
is in the rigor (AM state). The cross-bridges detach from the
rigor thus accumulating the myosin cross-bridges in nonforce
generating states. Subsequently, they reattach and produce
force due to the presence of high Ca
 
2
 
1
 
. ATP release from
caged ATP as well as detachment of cross-bridges from rigor
are very rapid processes being 200 s
 
2
 
1
 
 (34) and 4 
 
3 
 
10
 
4
 
 M
 
2
 
1
 
s
 
2
 
1
 
(35), respectively. Thus, we consider the tension development
to be the rate-limiting reaction.
Here we describe for the first time that ventricular fibers
with high amounts of ALC-1 revealed a higher 
 
V
 
max
 
 and lower
 
t
 
1/2
 
 than fibers with no or low amounts of ALC-1. These results
suggest that ALC-1 increases cycling kinetics of cardiac cross-
bridges thus regulating the contractile state of the heart.
 
Materials and Methods
 
Patient populations.
 
Right ventricular infundibular tissue was ob-
tained from 26 patients undergoing repair of congenital heart disease
in the German Heart Center (Berlin, Germany): five patients with
DORV, six patients with IPS, and 15 patients with TOF. Normal right
ventricular tissue was obtained from a 10-yr-old girl suffering from a
parasite infection. All samples were immediately chemically skinned
after resection. Hemodynamic data for all patients were available
from preoperative right heart catheterization. Informed consent was
obtained from all patients according to the local Ethical Committee.
 
Tissue preparation.
 
All biochemical as well as mechanical experi-
ments were performed with demembranated multicellular heart fi-
bers (skinned fibers) prepared as described previously (19). In short,
ventricular fiber bundles (about 1-mm thick, 1–6-mm long) were in-
cubated in a solution containing 20 mM imidazole, 10 mM NaN
 
3
 
,
5 mM ATP, 5 mM MgCl
 
2
 
, 4 mM EGTA, 2 mM DTE, 50% glycerol,
1% Triton x-100, pH 7, at 4
 
8
 
C for 18–20 h. Subsequently, the fibers
were transferred into the same solution but without Triton X-100 and
stored at 
 
2
 
20
 
8
 
C.
 
Biochemical analysis.
 
To obtain a direct correlation and to prevent
the influence of possible regional inhomogeneities of ALC-1 expres-
sion, myosin light chains of the same skinned fiber previously me-
chanically investigated were analyzed by a high-resolution two-
dimensional gel electrophoresis (2D PAGE) technique. Isoelectric
focussing (first dimension) was performed in glass capillaries (12.5-
cm long, 1-mm inner diameter) using the pH gradient 4.5–5.4 (phar-
malytes; Pharmacia, Sweden). The gels were run overnight at 600V
constant for the first dimensional separation. The second dimension
was a SDS-electrophoresis, using slab gels 10.5 
 
3
 
 9.5 cm, 1-mm thick.
The gels were stained with Coomassie blue and the MLC were evalu-
ated by computer-assisted scanner densitometry (ScanPack; Biome-
tra, Germany).
 
Mechanical analysis.
 
For all mechanical experiments, fibers were
dissected into bundles of 150–200-
 
m
 
m diam and 3–6-mm long under a
preparation microscope. Fibers were mounted isometrically between
a force transducer and a length step generator with micro syringes in
relaxation solution. Length was adjusted such that resting tension was
threshold, using a micrometer screw. Sarcomere length at resting ten-
sion was always between 1.95 and 2.0 
 
m
 
m as detected by laser diffrac-
tion analysis. Relaxation solution contained (mM): Imidazol (25),
ATP (10), creatinphosphate (10), MgCl
 
2
 
 (12.5), NaN
 
3
 
 (5), DTE (1),
EGTA (5), KCl (12.5), creatine kinase 380 U/ml, pH 7. Contraction
solution was the same as relaxation solution except that EGTA was
substituted by 5 mM CaEGTA. Ca
 
2
 
1
 
-free rigor solution contained:
2.5 mM MgCl
 
2
 
, 5 mM EGTA, 2 mM DTE, BDM (100 mM), pH 7.
Ca
 
2
 
1
 
-rigor contained: 2.5 mM MgCl
 
2
 
, 5 mM CaEGTA, 2 mM DTE,
pH 7. Photolysis solution was made by adding 5 mM 
 
P
 
3
 
-1-(2-nitro-
phenyl)-ethyladenosine-5
 
9
 
-triphosphate (caged-ATP; Calbiochem-
Behring Corp., San Diego, CA) and 10 mM DTE to the Ca
 
2
 
1
 
-rigor
solution. Ionic strength was adjusted with KCl to 130 mM. Free Ca
 
2
 
1
 
concentrations were calculated according to a commercially available
computer program (36).
 
Force-velocity measurements.
 
The fibers were transfered from re-
laxation (pCa 8) into maximally Ca
 
2
 
1
 
 activation solution (pCa 4.5).
Force-velocity relations were determined by isotonic quick releases
under constant load at 21
 
8
 
C using a commercially available setup
(Scientific Instruments, Heidelberg, Germany). Load clamping for
isotonic shortening was achieved by changing the mode of operation
from length control to force control during isometric steady state ten-
sion. The force during isotonic contraction was held constant by the
controlled motion of the length step generator, which followed the
contracting fiber with the appropriate velocity. The force control
mode was maintained for 250 ms. The velocity of the length step was
determined with an optoelectronical position detector. Both force
and velocity signals were displayed on a storage digital oscilloscope
(HM 408) and analyzed with an IBM compatible PC using the Pro-
scope Hameg Software SP91. Velocity was measured between 20 and
50ms after the onset of the quick release.
The relation between shortening velocity and force during iso-
tonic contraction was analyzed using a linearized form of the Hill
1938 (37) equation:
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(1)
 
v
 
 is the shortening velocity, 
 
P
 
 is the force during isotonic contraction,
 
P
 
0
 
 is the maximal isometric steady state force, and a and b are con-
stants. Maximal shortening velocity (
 
V
 
max
 
) was determined by extrap-
olation of Eq. 
 
1
 
 to zero-load.
 
Measurements of half-time of tension development (t
 
1/2
 
).
 
Dissected
fiber bundles were mounted isometrically in a 40 
 
m
 
l quartz cuvette
(Scientific Instruments, Heidelberg, Germany). Photolysis of caged
ATP was achieved using a xenon flash lamp system (G. Rapp Opto-
electronic, Hamburg, Germany). The lamp delivered UV light pulses
with a duration of about 1 ms and was focused through a UG-11 filter.
Force signals were displayed on a storage digital oscilloscope (HM
408) and analyzed with an IBM compatible PC. The experimental de-
sign was the same as elaborated previously (21). In short, the fibers
were mounted isometrically and incubated in relaxation solution and
subsequently in Ca
 
2
 
1
 
-free rigor solution containing 100 mM BDM for
30 min. In the presence of BDM, a “low-tension rigor” developed
(21). Subsequently, the fibers were transferred in Ca
 
2
 
1
 
-containing
rigor solution (pCa 4.5) for 4 min and then in Ca
 
2
 
1
 
 containing rigor
plus 5 mM caged-ATP for 5 min. After registration of force develop-
ment induced upon a light flash, the fiber was incubated in relaxation
solution and subsequently in maximally contraction solution (pCa
4.5). Temperature was always 21
 
8
 
C.
P a+( ) v b+( ) P0 a+( ) b=
 
Statistical analysis.
 
All statistical analysis were performed using
commercially available statistic programs (Enzfitter, Epistat) on an
IBM compatible PC. Values are means
 
6
 
SEM. Significance analysis
was performed using the Student’s t-test for unpaired values. Regres-
sion analysis was performed by the least-squares method.
 
Results
 
Hemodynamic Data
 
Pressure difference between right ventricle and pulmonary ar-
tery of all patient groups was between 15 and 120 mmHg (Ta-
ble I). The mean pressure difference of all patients investi-
gated (24 patients) was 71.6
 
6
 
6.0 mmHg.
 
Myosin Light Chain Analysis
 
The MLC isoforms were analyzed according to their isoelec-
tric point and molecular weight by 2D-PAGE. The ALC-1 re-
vealed a higher molecular weight and was more acidic than the
VLC-1. Fig. 1 shows two original gels of a multicellular de-
membranated right ventricular preparation of a normal pa-
tient (
 
left
 
) and a patient with TOF (
 
right
 
). Both fibers con-
tained VLC-1, VLC-2, and VLC-2* but the TOF preparation
contained in addition the ALC-1.
The mean ALC-1 expression of all patients with congenital
heart disease (26 patients) was 8.5
 
6
 
1.4%. However, not all pa-
tients contained ALC-1: 5 patients out of the 26 patients inves-
tigated in this study were virtually free of ALC-1 in the right
ventricular infundibulum. Those patients who expressed ALC-1
revealed very different amounts ranging from 2 up to 27.2%
ALC (expressed in % of MLC-1, i.e., ALC-1 
 
1
 
 VLC-1 
 
5
 
100%) (Table I).
The ratio between MLC-1 and MLC-2 was the same in all
patient groups. In the normal heart, the MLC-1/MLC-2 ratio
was 1.1
 
6
 
0.02 (one patient). Taking all patients together (26
patients) we observed a MLC-1/MLC-2 ratio of 1.07
 
6
 
0.03%.
We could not find any differences in the expression of ven-
tricular MLC-2 isoforms (VLC-2 and VLC-2*) in the right
ventricular fibers. In normal heart fibers, 70.6% of the MLC-2
forms was VLC-2. Taking all patients with congenital heart
disease (26 patients) we observed a mean value of 70.3
 
6
 
1.3%.
Both MLC-2 isoforms of all ventricular fiber preparations
were completely dephosphorylated. The ALC-2 was never ob-
served in our right ventricular fibers.
Figure 1. Original photographs of MLC in the right ventricle of the 
human heart. MLC were analyzed by 2D-PAGE and stained with 
Coomassie-blue. (Left) Right ventricular tissue of a patient with Te-
tralogy of Fallot. (Right) Right ventricular tissue of a normal heart. 
ALC-1 and VLC-1 correspond to the atrial and ventricular essential 
MLC, respectively. VLC-2 and VLC-2* correspond to the ventricular 
regulatory MLC isoforms. TM, tropomyosin.
 
Table I.
 
Patient
number Age Diagnosis Sex ALC-1
 
6
 
SEM
 
D
 
 P (mm Hg) Vmax
 
6
 
SEM
 
yr % ML/s
 
2 0.08 TOF female 18.30
 
6
 
1.20 92.00 1.67
 
6
 
0.07
42 2.00 DORV female 13.90
 
6
 
0.90 130.00 1.45
 
6
 
0.10
43 55.10 DORV male 5.00
 
6
 
0.50 63.00 1.57
 
6
 
0.25
23 1.00 TOF male 14.00
 
6
 
0.80 70.00 1.81
 
6
 
0.08
24 1.00 TOF female 19.90
 
6
 
1.30 85.00 2.25
 
6
 
0.11
33 1.55 TOF male 15.00
 
6
 
0.70 130.00 1.75
 
6
 
0.15
34 54.00 IPS female 0.00
 
6
 
1.10 115.00 1.24
 
6
 
0.10
36 10.50 IPS female 3.00
 
6
 
0.20 60.00 nd
38 2.40 TOF male 5.00
 
6
 
0.30 67.00 nd
39 2.90 IPS female 4.00
 
6
 
0.15 60.00 1.52
 
6
 
0.06
48 5.75 TOF female 3.00
 
6
 
0.10 73.00 1.61
 
6
 
0.08
50 3.40 TOF male 2.00
 
6
 
0.10 68.00 nd
53 1.00 TOF male 12.30
 
6
 
1.10 80.00 nd
55 17.20 TOF male 7.70
 
6
 
0.80 75.00 nd
45 2.70 DORV male 4.00
 
6
 
0.50 60.00 1.26
 
6
 
0.08
58 1.10 TOF female 9.50
 
6
 
1.10 nd nd
59 2.50 TOF female 0.00 nd nd
60 10.40 TOF female 18.00
 
61.10 60.00 nd
61 7.80 IPS female 0.0060.00 20.00 nd
62 51.50 TOF male 0.0060.00 110.00 1.2260.11
63 0.95 TOF male 11.4061.20 80.00 nd
64 5.40 IPS male 10.6060.90 65.00 nd
49 1.20 IPS female 11.0061.00 35.00 nd
67 2.25 TOF male 8.0060.50 65.00 nd
68 10.10 normal female 0.0060.00 nd 1.2060.10
66 0.50 DORV female 27.2461.90 15.00 nd
47 0.10 DORV male 6.0060.40 40.00 nd
Hemodynamic (right ventricular pressure difference DP), biochemical
(ALC-1 expression in % fo MLC-1), and physiological data (Vmax in
muscle length per second) of right ventricle of the heart from patients
with congenital heart diseases. (TOF 5 Tetralogy of Fallot; DORV 5
double outlet right ventricle; IPS 5 infundibular pulmonary stenosis).
nd, not determined.
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There was no statistically significant difference between
the pressure difference of patients with and without ALC-1:
patients without ALC-1 revealed a pressure differerence of
81.6625.5 mmHg (three patients), the patients with ALC-1 (21
patients) had a pressure difference of 70.165.7%. There was
no correlation between pressure difference and ALC-1 expres-
sion (Fig. 2).
Mechanical Analysis
Isometric force production. Isometric steady-state tension (mN)
per cross-sectional area (mm2) was obtained from skinned fi-
bers maximally activated in contraction solution (pCa 4.5). 15
right ventricular fibers of three different patients with 0%
ALC-1 (obtained from a normal heart, a patient with IPS, and
a patient with TOF) was 352.6646.6 mN/mm2. We observed
significantly higher force productions per cross-sectional area
with increasing ALC-1 expression: fibers with 0% ALC-1 (six
normal fibers), fibers containing 3–5% ALC-1 and six differ-
ent fibers of a TOF patient with 19.9% ALC-1 revealed
660673 mN/mm2 (P , 0.01) and 835.36102 mN/mm2 (P ,
0.01), respectively.
Force-velocity measurements. Force-velocity measurements
could be performed with skinned right ventricular fiber prepa-
rations of 11 patients and one normal since in most cases tissue
was not sufficient for combined biochemical and mechanical
analysis. The force-velocity data of all fibers could well be fit-
ted to a hyperbolic function. Fig. 3 shows representative curves
of three patients with different amounts of ALC-1 expression.
Please note from Fig. 3, that Vmax of the human right ventricu-
lar fibers increased with increasing amounts of ALC-1 present.
Plotting the ALC-1 expression versus the Vmax values of all
patients studied (means of 12 different patients and one nor-
mal heart, six fibers per patients), we observed a significant
positive correlation between both parameters (Fig. 4). Evalua-
tion of the relationship between ALC-1 and Vmax by linear re-
gression analysis revealed the equation:
This correlation was statistically significant (P , 0.01). Com-
paring Vmax of patients with two different ALC-1 expression
values, i.e., 0% ALC-1 and 19.9% ALC-1 we observed a statis-
tically significant (P , 0.001) increase from 1.260.06 ML/s
(normal heart, six fibers) to 2.2660.1 ML/s (TOF, six fibers),
respectively.
y 0.029x 1.378+=
Figure 2. Correlation between DP expressed in mmHg and ALC-1 
expression (in % of MLC-1 isoforms) of 27 patients with congenital 
heart diseases (TOF, DORV, IPS) and one normal heart.
Figure 3. Force-velocity curves of skinned right ventricular fibers of 
patients with different amounts of ALC-1 in the ventricle (19.9, 15.5, 
and 0% ALC-1). P0 is maximal isometric force, P is the force during 
isotonic shortening. Shortening velocity is expressed in ML/s. Values 
are means of six different fibers each.
Figure 4. Correlation between ALC-1 expression (expressed in % 
MLC-1 isoforms) and maximal shortening velocity (Vmax) expressed 
in ML/s of demembranated right ventricular fibers. Values are means 
6SEM. Analysis of Vmax and ALC-1 of six different fibers per patient.
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In addition to Vmax, the curvature of the force-velocity rela-
tion changed with different ALC-1 expression levels. In-
creased ALC-1 levels was associated with a decrease of a/P0.
Right ventricular fibers containing 0% ALC-1 revealed an a/P0
ratio of 0.2160.02 (normal heart, six fibers). Fibers with 19.9%
ALC-1 had an a/P0 of 0.1560.02 (TOF patients, six fibers).
There was no correlation between the age of the patients
and Vmax. Although the patients with 0% ALC-1 were of dif-
ferent age, they had similar and not statistically different
Vmax, namely 1.260.06 ML/s (normal heart, 10 yr), 1.2460.1
ML/s (IPS, 54 yr), and 1.2260.11 ML/s (TOF, 51.5 yr).
Half-time of force development (t1/2). Half-times of tension
development of skinned human heart fibers were determined
from the force-transient elicited upon photolytical release of
ATP from caged ATP in low-tension rigor. Fig. 5 shows two
superimposed original registrations of the tension transients of
a fiber with 2% ALC-1 and a fiber with 18.4% ALC-1. Right
ventricular fibers from a TOF patient with 2% ALC-1 re-
vealed a significantly higher t1/2 than a patient with TOF con-
taining 18.4% ALC-1: t1/2 was 0.25260.04 s (six fibers) and
0.13660.016 s (six fibers) (P , 0.05), respectively (Fig. 5). This
indicates a 1.85-fold faster kinetics of tension development of
myosin cross-bridges with high ALC-1 expression compared to
those with low ALC-1.
Depletion of ADP by incubation of the fibers with apyrase
(30 U/ml; Sigma) in rigor solution prior to the light-flash had
no influence on kinetics of tension development: t1/2 of an apy-
rase-treated TOF fiber with 2% ALC-1 was 0.23660.02 s
(three fibers) (not shown).
Discussion
Expression of the embryonic (5atrial) MLC-1 (MLC-1emb or
ALC-1) is developmentally regulated: It is expressed in stri-
ated muscle types during embryonic and early postnatal devel-
opment and declines rapidly during postnatal development but
it remains in the atrium during the whole life-span (8, 13, 14).
In the right ventricular infundibulum of patients with congeni-
tal heart disease, however the developmentally dependent de-
cline of ALC-1 expression is much slower than in normal
hearts (14). The relative persistence of the ALC-1 expression
in patients with congenital heart disease could be explained by
the high pressure overload caused by the right ventricular out-
flow obstruction and the development of right ventricular hy-
pertrophy. In fact, a positive correlation between pressure
overload in adult patients with valvular heart disease and
ALC-1 expression in the left ventricle exists (18). Normaliza-
tion of the hemodynamic state by valve replacement signifi-
cantly reduced hypertrophy and ALC-1 expression (18). In
young patients with congenital heart disease, however, at least
two opposing factors exist regulating ALC-1 expression into
different directions: decrease of ALC-1 expression with age
and an upregulation of ALC-1 expression due to the high pres-
sure overload. The existence of these counterbalancing factors
which determine ALC-1 expression may be one of the causes
of the missing correlation between pressure gradient and
ALC-1 expression in patients with congenital heart diseases.
ALC-1 expression besides VLC-1, VLC-2, and VLC-2* in
the human ventricle raises the question whether there is a
compensatory down-regulation of the ventricular MLC iso-
forms. This could be answered by comparing the ratios be-
tween MLC-1 and MLC-2 which, according to the generally
accepted myosin model ought to be 1.0 (i.e., each MHC mono-
mer associated with one essential and one regulatory MLC)
(1, 17). The MLC-1/MLC-2 ratio in the normal ventricle was
indeed around one as predicted from the myosin model. This
ratio did not change with additional ALC-1 expression in pa-
tients with congenital heart diseases. Thus, we suspect that
there is a compensatory downregulation of the VLC-1 expres-
sion in order to maintain the normal MLC-1/MLC-2 ratio.
Although many reports have demonstrated the expression
of ALC-1 in the adult ventricle of patients with congenital or
congestive heart diseases (14, 15, 17, 18), the functional conse-
quences of essential myosin light chains remained unclear.
Some work with skeletal muscle fibers suggest that essential
myosin light chains play a role in shortening velocity (24, 25)
but these studies are limited due to the coexistence of different
myosin heavy chain isoforms in the fibers. In a recent study,
which considered more carefully the myosin heavy chain varia-
tion in skeletal muscle fibers, maximal shortening velocity cor-
related negatively with the amount of MLC-3f (26). However,
MLC-3 is an alternatively spliced isoform of the MLC-1 which
lacks the first 41 NH2-terminal amino acids and which does not
exist in the heart (27, 28).
In this study we analyzed the role of essential MLC on
cross-bridge cycling kinetics of the human heart. We measured
maximal shortening velocity (Vmax) and half-time of tension
development (t1/2) of demembranated multicellular fibers
(skinned fibers) prepared from the right ventricular infundibu-
lum obtained from patients with congenital heart defects
(TOF, DORV, or IPS). To guarantee selective analysis of my-
osin function and to exclude the influence of changes of regu-
latory proteins, we investigated Vmax and t1/2 at maximal Ca21
activation (pCa 4.5). Different expression of MHC in the nor-
mal and hypertrophied infundibulum could be excluded since
only the b-MHC was found to be expressed (14).
The important observations in this paper are that ALC-1
expression was associated with increased isometric tension,
Vmax, and velocity of tension development (decrease of t1/2).
Since we have chosen our experimental conditions such that
the behavior of the myosin cross-bridge is considered and
since only the essential MLC isoforms changed we feel justi-
fied to causally relate myosin cross-bridge kinetics and con-
tractility to essential MLC expression.
Figure 5. Original force registrations with high time-resolution from 
caged-ATP experiments on multicellular demembranated right ven-
tricular fibers of two TOF patients with different amounts of ALC-1 
(% of MLC-1). All experiments were performed in low tension rigor 
achieved by incubation in rigor solution with BDM. Arrow indicates 
photolysis of caged-ATP. Please note that fibers with high ALC-1 de-
veloped faster isometric force than the fiber with low ALC-1.
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Increased isometric tension per cross-section is interesting
since it allows some speculations concerning the characteristics
of myosin cross-bridges: steady-state isometric force F of a
muscle fiber can be described by the equation:
 (2)
where F9 is the force generation per cross-bridge, ntot is the to-
tal amount of cycling cross-bridges per half-sarcomere, fapp is
the rate-constant for transition from nonforce into force-gen-
erating state (attachment rate), and gapp is the rate-constant for
the transition of cross-bridges from force into nonforce gener-
ating states (detachment rate) (31). It seems to be unlikely that
ntot changed since we activated our fibers at maximal Ca21
concentrations (pCa 4.5). Thus, both F9 as well as the cross-
bridge–cycling kinetics (fapp and/or gapp) may change with
ALC-1 expression.
According to the cross-bridge hypothesis of A.F Huxley
1957 (38), Vmax depends on the detachment rate constant of
negatively strained cross-bridges and, therefore provides infor-
mation of the cross-bridge cycling kinetics. Normal ventricular
fibers revealed a Vmax of 1.2 mL/s by extrapolation of the force-
velocity curve to zero-load. Calculation of Vmax from the ALC-
1-Vmax regression line revealed a normal value of about 1.4
mL/s (fibers with 0% ALC-1 as determined from the intercept
with the Y axis). These normal Vmax values of human ventricle
are in agreement with our previous determination using the
slack-test technique (44). We found a significant positive cor-
relation between ALC-1 expression and Vmax. From two ex-
treme points of the ALC-1-Vmax correlation (0 and 19.9%
ALC-1) we calculated a 1.85-fold increase of Vmax. This result
demonstrates the strong influence of essential MLC on cross-
bridge cycling kinetics in the heart: myosin cross-bridges with
the composition b-MHC/ALC-1/VLC-1/VLC-2/VLC-2* re-
vealed a higher detachment rate than myosin cross-bridges
with the compostition b-MHC/VLC-1/VLC-2/VLC-2*.
An additional factor which might influence Vmax is the pres-
ence of “internal loads” due to different amounts of connec-
tive tissue. Fibrosis of cardiac tissue is a common observation
in cardiac hypertrophy and during development (39). Theoret-
ically, frictional forces should decrease shortening velocity and
the curvature of the force-velocity relationship, hence increas-
ing a/P0. However, we observed an increased Vmax and de-
creased a/P0 in the hypertrophied hearts of patients with con-
genital heart disease. Furthermore, there was no correlation
between age and Vmax which has to be predicted if the degree
of fibrosis would have determined Vmax: Vmax of all ventric-
ular fibers with no ALC-1 (three patients) were in the same
range despite the very different ages of the patients (8–54 yr).
We cannot exclude the possibility, however, that we underesti-
mated the positive influence of ALC-1 expression on cardiac
contractility since high internal loads in the hypertrophied
hearts may have balanced ALC-1 effects.
Transition of cross-bridges from non-force into force gen-
erating states measured as half-time of tension development
(expressed as t1/2) during maximal Ca21 activation of ventricu-
lar fibers was lower in the presence of high compared to fibers
with low amounts of ALC-1. We consider the thin filament
regulatory system to be fully activated under our experimental
conditions, hence t1/2 reflects the transition from non-force into
force-generating states. When analyzed according to a two-
state model (cf. 31, 38), t1/2 equals (fapp 1 gapp). We cannot de-
cide which kinetic parameter increased by additional expres-
F F9 ntot fapp/ fapp gapp+( )=
sion of ALC-1 (fapp or gapp or both). Due to its effect on Vmax
we can, however, speculate that it is at least an increased de-
tachment rate which is responsible for the ALC-1-induced in-
creased velocity of tension development.
Increasing the phosphorylation level of the regulatory
MLC of the heart catalyzed by a Ca21 calmodulin-dependent
MLC kinase increased the Ca21 sensitivity of the isometric ten-
sion production in the animal (19) and human (20) heart. The
increased Ca21 sensitivity could be explained at least partially
by an increased attachment-rate constant of the myosin cross-
bridge upon MLC-2 phosphorylation (21). Since the regula-
tory light chains were completely dephosphorylated, we can
rule out an influence of different phosphorylated states of the
fibers on isometric tension, Vmax, and t1/2. The fibers were com-
pletely dephosphorylated because we used Ca21-free condi-
tions for preparation. Under this condition, the myosin light
chain kinase which is Ca21 calmodulin dependent, is inactive
while the light chain phosphatase remains active leading to a
dephosphorylation (20).
ADP can bind to rigor cross-bridges and affect the detach-
ment rate (32). However, depletion of the fibers from ADP by
apyrase-treatment had no influence on t1/2 of skinned ventricu-
lar fibers. The molecular mechanism explaining the effect of
essential MLC in the heart may reside in the mode of interac-
tion between MLC-1 and actin. It has been demonstrated that
the amino-terminal domain of MLC-1 isoforms bind to the
carboxyl-terminal domain of actin (40, 41). This interaction
could be of functional importance since inhibition of this inter-
action using synthetic peptides increased force production and
shortening velocity of human heart fibers (22). We proposed
that MLC-1-actin interaction imposes a kind of “molecular load”
on the myosin cross-bridge. Relieving this load increases con-
tractility. Interestingly, the primary structure of the most amino
terminus of the ALC-1 and VLC-1 are different (10), suggest-
ing different binding strength between ALC-1, VLC-1, and actin.
In our hands, binding of ALC-1 to actin should be weaker than
binding of VLC-1 thus decreasing the “molecular load” im-
posed on the cross-bridge. This would, in analogy to weaken-
ing MLC-1-actin interaction by peptides, explain the increased
force production and accelerated cross-bridge cycling kinetics
associated with ALC-1 expression in the human ventricle.
Regulation of cardiac contractility by expression of differ-
ent essential MLC isoforms in the human ventricle is different
from the mode of regulation in the rodent heart. It is now well
established that rodents change their MHC rather than MLC
expression due to hormonal, developmental, or hemodynamic
changes or as response to different environmental demands
(43). In these species a-MHC expression increased shortening
velocity, energy consumption, and oxygen consumption while
an increased expression of the b-MHC decreased these pa-
rameters (43).
In summary, we presented evidence for an upregulation of
cross-bridge cycling kinetics and contractility of the hypertro-
phied human ventricle caused by the expression of the ALC-1.
The human ventricle, therefore seems to regulate its contrac-
tility by changing MLC rather than MHC isoforms which is
common for rodents.
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